New Drug Application Updates, Appointments, Partnership Programs, and Stock Movements - Research Report on Amarin, Oramed

 New Drug Application Updates, Appointments, Partnership Programs, and Stock
     Movements - Research Report on Amarin, Oramed Pharmaceuticals, Synta
                Pharmaceuticals, Healthways and AMN Healthcare

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, December 25, 2013

NEW YORK, December 25, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Amarin
Corporation plc (NASDAQ: AMRN), Oramed Pharmaceuticals Inc. (NASDAQ: ORMP),
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), Healthways Inc. (NASDAQ: HWAY),
and AMN Healthcare Services Inc. (NYSE: AHS). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Amarin Corporation plc Research Report

On December 20, 2013, Amarin Corporation plc (Amarin) announced that it has
been notified by the U.S. Food and Drug Administration (FDA) that the FDA
does not expect to take action on the Company's supplemental new drug
application (sNDA) for the proposed ANCHOR indication labeling expansion for
Vascepa® (icosapent ethyl) capsules on the December 20, 2013, Prescription
Drug User Fee Act (PDUFA) goal date since the Company's request to re-instate
the ANCHOR Special Protocol Assessment (SPA) agreement is under consideration
with the FDA. Amarin added that no new PDUFA date has been decided. The
Company also stated that FDA intends to complete its review of Amarin's
request to re-instate the ANCHOR SPA agreement and to inform its decision to
Amarin before January 15, 2014. In another release dated December 16, 2013,
Amarin announced the appointment of current President, John F. Thero, as
President and CEO of the Company, along with his appointment to the Board of
Directors, effective January 1, 2014. The Company further informed that Joseph
S. Zakrzewksi will retire as CEO and Chairman, and Lars Ekman, MD, PhD,
current Lead Independent Director, will become Chairman of the Board,
effective January 1, 2014. The Full Research Report on Amarin Corporation plc
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/7cf9_AMRN

--

Oramed Pharmaceuticals Inc. Research Report

On December 20, 2013, Oramed Pharmaceuticals Inc.'s (Oramed Pharmaceuticals)
stock rallied 48.95%, closing the day at $10.65. Over the past three trading
days, the Company's stock surged 53.24%, compared to the Dow Jones Industrial
Average, which advanced 2.18% during the same three day trading period. The
Full Research Report on Oramed Pharmaceuticals Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/c199_ORMP

--

Synta Pharmaceuticals Corp. Research Report

On December 20, 2013, Synta Pharmaceuticals Corp. (Synta) announced that it
has appointed Steven Bernitz as Senior Vice President, Corporate Development.
The Company stated that Mr. Bernitz has over 20 years of experience in
corporate strategy, business leadership and transactional experience in life
sciences, and was a General Partner and Head of the BioPharma Practice at
Extera Partners, before joining Synta. Commenting on the appointment, Safi
Bahcall, President and CEO, Synta, stated, "Steve has tremendous deal
experience, as is clear from his track record, which will be valuable in
realizing the potential of both our ganetespib and HDC programs. His wealth of
diverse business experiences and insights make him an excellent addition to
our executive team, as we manage a growing pipeline and an increasing number
of important strategic and operational choices." The Full Research Report on
Synta Pharmaceuticals Corp. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/8ecc_SNTA

--

Healthways Inc. Research Report

On December 17, 2013, Healthways Inc. (Healthways) reported that Freedom
Health and Optimum Healthcare have partnered with the Company to offer the
award-winning SilverSneakers® Fitness Program to eligible Medicare Advantage
members through 2016. According to the Company, SilverSneakers is a leading
exercise program designed exclusively for older adults, and has proven to
reduce healthcare costs and improve physical, cognitive and social well-being
of its members. Healthways stated that SilverSneakers will be available to
eligible Medicare Advantage members of Freedom Health and Optimum HealthCare
plans in Florida, starting January 1, 2014. Commenting on the release, Ben R.
Leedle, Jr., Healthways President and CEO, stated, "By offering
SilverSneakers, Freedom Health and Optimum HealthCare are fulfilling the needs
of their eligible older-adult Medicare Advantage members by promoting
wellness, embracing innovation and pursuing excellence in the delivery of
healthcare. We look forward to partnering with Freedom Health and Optimum
HealthCare in providing this time-tested, proven program to their members and
helping them realize higher well-being and greater quality of life." The Full
Research Report on Healthways Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/76fd_HWAY

--

AMN Healthcare Services Inc. Research Report

On December 20, 2013, AMN Healthcare Services Inc.'s (AMN Healthcare) stock
went up by 6.54%, closing at $14.49. For the past three trading days, the
Company's stock gained 5.00%, compared to the Dow Jones Industrial Average,
which moved up 2.18% over the same three day trading period. The Full Research
Report on AMN Healthcare Services Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/b6d6_AHS

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.